aminosalicylic acid has been researched along with HIV Coinfection in 8 studies
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.
4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| " A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index." | 6.79 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. ( de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| " Hypothyroidism is a common AE associated with ethionamide, p-aminosalicylic acid (PAS), and stavudine." | 3.79 | High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. ( Andries, A; Dalal, A; Das, M; Desai, C; Fernandes, D; Isaakidis, P; Khan, S; Mansoor, H; Migliori, GB; Paryani, R; Saranchuk, P; Sotgiu, G; Verma, R, 2013) |
| " Clinical data, serum thyroid stimulating hormone (TSH) and free thyroxine (fT4) levels were retrospectively assessed in 137 children receiving anti-tuberculosis treatment including ETH." | 3.77 | Abnormal thyroid function tests in children on ethionamide treatment. ( Hesseling, AC; Magdorf, K; Schaaf, HS; Thee, S; Willemse, M; Zöllner, EW, 2011) |
| " A PAS population pharmacokinetic model in two dosing regimens was developed; potential covariates affecting its pharmacokinetics were examined, and Monte Carlo simulations were conducted evaluating the pharmacokinetic-pharmacodynamic index." | 2.79 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. ( de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M, 2014) |
| " A population pharmacokinetic model was developed describing PAS pharmacokinetics in children receiving routine RR-TB treatment." | 1.72 | Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. ( Chirehwa, M; Denti, P; Donald, PR; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Mao, J; McIlleron, H; Norman, J; Schaaf, HS; van der Laan, LE; Wiesner, L; Winckler, JL, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 1 |
| Schaaf, HS | 2 |
| Chirehwa, M | 1 |
| Winckler, JL | 1 |
| Mao, J | 1 |
| Draper, HR | 1 |
| Wiesner, L | 1 |
| Norman, J | 1 |
| McIlleron, H | 1 |
| Donald, PR | 2 |
| Hesseling, AC | 2 |
| Denti, P | 1 |
| Pietersen, E | 1 |
| Anderson, K | 1 |
| Cox, H | 1 |
| Dheda, K | 1 |
| Bian, A | 1 |
| Shepherd, BE | 1 |
| Sterling, TR | 1 |
| Warren, RM | 1 |
| van der Heijden, YF | 1 |
| Parvez, MM | 1 |
| Kalkisim, S | 1 |
| Nguyen, PTT | 1 |
| Jung, JA | 1 |
| Park, JK | 1 |
| Ghim, JL | 1 |
| Kim, EY | 1 |
| Cho, YS | 1 |
| Babaoglu, MO | 1 |
| Shin, JG | 1 |
| Park, S | 1 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Shim, TS | 1 |
| Mpagama, SG | 1 |
| Heysell, SK | 1 |
| Ndusilo, ND | 1 |
| Kumburu, HH | 1 |
| Lekule, IA | 1 |
| Kisonga, RM | 1 |
| Gratz, J | 1 |
| Boeree, MJ | 1 |
| Houpt, ER | 1 |
| Kibiki, GS | 1 |
| Andries, A | 1 |
| Isaakidis, P | 1 |
| Das, M | 1 |
| Khan, S | 1 |
| Paryani, R | 1 |
| Desai, C | 1 |
| Dalal, A | 1 |
| Mansoor, H | 1 |
| Verma, R | 1 |
| Fernandes, D | 1 |
| Sotgiu, G | 1 |
| Migliori, GB | 1 |
| Saranchuk, P | 1 |
| de Kock, L | 1 |
| Sy, SK | 1 |
| Rosenkranz, B | 1 |
| Diacon, AH | 1 |
| Prescott, K | 1 |
| Hernandez, KR | 1 |
| Yu, M | 1 |
| Derendorf, H | 1 |
| Thee, S | 1 |
| Zöllner, EW | 1 |
| Willemse, M | 1 |
| Magdorf, K | 1 |
1 trial available for aminosalicylic acid and HIV Coinfection
| Article | Year |
|---|---|
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Adult; Alkynes; Aminosalicylic Acid; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cr | 2014 |
7 other studies available for aminosalicylic acid and HIV Coinfection
| Article | Year |
|---|---|
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Child; Drug Administration Schedule; HIV Infectio | 2022 |
Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Ethionamide; Female; HIV Infections; Ho | 2023 |
Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research.
Topics: Aminosalicylic Acid; Drug Interactions; HIV Infections; Humans; Male; Research Subjects; Tenofovir; | 2022 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.
Topics: Adult; Aminoglycosides; Aminosalicylic Acid; Antitubercular Agents; Comorbidity; Drug Resistance, Mu | 2013 |
High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.
Topics: Adult; Aminosalicylic Acid; Cohort Studies; Coinfection; Ethionamide; Female; HIV Infections; Humans | 2013 |
Abnormal thyroid function tests in children on ethionamide treatment.
Topics: Adolescent; Aminosalicylic Acid; Antitubercular Agents; Child; Child, Preschool; Ethionamide; Euthyr | 2011 |